000 01771 a2200505 4500
005 20250513121341.0
264 0 _c19970708
008 199707s 0 0 eng d
022 _a0340-7004
024 7 _a10.1007/s002620050371
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSharkey, R M
245 0 0 _aAdvantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
_h[electronic resource]
260 _bCancer immunology, immunotherapy : CII
_cMay 1997
300 _a179-88 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal
_xpharmacokinetics
650 0 4 _aAntigens, CD
_ximmunology
650 0 4 _aAntigens, Differentiation, B-Lymphocyte
_ximmunology
650 0 4 _aAntigens, Neoplasm
_ximmunology
650 0 4 _aCell Adhesion Molecules
650 0 4 _aHumans
650 0 4 _aIndium Radioisotopes
_xpharmacokinetics
650 0 4 _aLectins
650 0 4 _aLymphoma, B-Cell
_ximmunology
650 0 4 _aMice
650 0 4 _aMice, Nude
650 0 4 _aNeoplasms, Experimental
_ximmunology
650 0 4 _aRadioimmunotherapy
650 0 4 _aSialic Acid Binding Ig-like Lectin 2
650 0 4 _aTumor Cells, Cultured
700 1 _aBehr, T M
700 1 _aMattes, M J
700 1 _aStein, R
700 1 _aGriffiths, G L
700 1 _aShih, L B
700 1 _aHansen, H J
700 1 _aBlumenthal, R D
700 1 _aDunn, R M
700 1 _aJuweid, M E
700 1 _aGoldenberg, D M
773 0 _tCancer immunology, immunotherapy : CII
_gvol. 44
_gno. 3
_gp. 179-88
856 4 0 _uhttps://doi.org/10.1007/s002620050371
_zAvailable from publisher's website
999 _c9172502
_d9172502